Interpretation of Updated NCCN Guidelines for Colon Cancer and Rectal Cancer （Version 1.2019）

doi:10.12114/j.issn.1007-9572.2019.00.655

Abstract

Abstract: Compared with NCCN Guidelines for Colon Cancer and Rectal Cancer （Version 4.2018），the NCCN Guidelines for Colon Cancer and Rectal Cancer （Version 1.2019） have made some significant updates that can change clinical practice.This paper analyses and interprets the most important updates in the NCCN Guidelines for Colon Cancer and Rectal Cancer （Version 1.2019），which mainly include：（1） BRAF WT was added as an indication for treatment，where KRAS and NRAS WT are noted；（2） Microsatellite Instability （MSI） or Mismatch Repair （MMR） Testing was modified and supplemented：BRAF V600E mutation and the diagnosis of Lynch syndrome，the result and meaning of immunohistochemistry；（3）The following regimens were added as treatment options in subsequent therapy：dabrafenib + trametinib + （cetuximab or panitumumab），encorafenib + binimetinib + （cetuximab or panitumumab）.The purpose of this article was to provide a reference for clinical selection of diagnosis and treatment options of colorectal cancer.

Key words: Colorectal neoplasms, Guidebooks, National Comprehensive Cancer Network, BRAF gene, Lynch syndrome

摘要： 2019.V1版《NCCN结直肠癌诊治指南》与2018.V4版《NCCN结直肠癌诊治指南》相比，其做出了一些能改变临床实践的更新。本文就2019.V1版《NCCN结直肠癌诊治指南》中最为重要的几个更新要点进行了分析与解读，主要包括：（1）新增“BRAF基因”作为指导治疗的一个指标；在所有标记“KRAS野生型和NRAS野生型”作为指征的地方，同时需标记“BRAF野生型”；（2）“微卫星不稳定性（MSI）和错配修复基因（MMR）检测”章节中对“BRFA基因V600E突变与林奇综合征相关性的内容”做了修改和补充，并且说明了免疫组化检查的结果及其含义；（3）新增了2个针对BRAF基因V600E突变患者的后续治疗方案：达拉非尼+曲美替尼+（西妥昔单抗或帕尼单抗）和康奈非尼+比美替尼+（西妥昔单抗或帕尼单抗）。本文旨在为临床诊断、治疗结直肠癌的策略选择提供参考。

关键词: 结直肠肿瘤, 指南, 美国国家综合癌症网络, BRAF基因, 林奇综合征

BAI Xueshan,LIN Guole. Interpretation of Updated NCCN Guidelines for Colon Cancer and Rectal Cancer （Version 1.2019）　[J]. Chinese General Practice, 2019, 22(33): 4031-4034. DOI: 10.12114/j.issn.1007-9572.2019.00.655.
白雪杉,林国乐. 2019.V1版《NCCN结直肠癌诊治指南》更新要点解析[J]. 中国全科医学, 2019, 22(33): 4031-4034. DOI: 10.12114/j.issn.1007-9572.2019.00.655.

References

［1］CEJAS P，LóPEZ-GóMEZ M，AGUAYO C，et al.KRAS mutations in primary colorectal cancer tumors and related metastases：a potential role in prediction of lung metastasis［J］.PLoS One，2009，4（12）：e8199.DOI：10.1371/journal.pone.0008199.
［2］KAWAZOE A，SHITARA K，FUKUOKA S，et al.A retrospective observational study of clinicopathological features of KRAS，NRAS，BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer［J］.BMC Cancer，2015，15：258.DOI：10.1186/s12885-015-1276-z.
［3］DAVIES H，BIGNELL G R，COX C，et al.Mutations of the BRAF gene in human cancer［J］.Nature，2002，417（6892）：949-954.DOI：10.1038/nature00766.
［4］YAMAUCHI M，MORIKAWA T，KUCHIBA A，et al.Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum［J］.Gut，2012，61（6）：847-854.DOI：10.1136/gutjnl-2011-300865.
［5］SAMOWITZ W S，SWEENEY C，HERRICK J，et al.Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers［J］.Cancer Res，2005，65（14）：6063-6069.DOI：10.1158/0008-5472.CAN-05-0404.
［6］SARIDAKI Z，PAPADATOS-PASTOS D，TZARDI M，et al.BRAF mutations，microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome［J］.Br J Cancer，2010，102（12）：1762-1768.DOI：10.1038/sj.bjc.6605694.
［7］MARGONIS G A，BUETTNER S，ANDREATOS N，et al.
Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer［J］.JAMA Surg，2018，153（7）：e180996.DOI：10.1001/jamasurg.2018.0996.
［8］QIU T，LU H Z，GUO L，et al.Detection of BRAF mutation in Chinese tumor patients using a highly sensitive antibody immunohistochemistry assay［J］.Sci Rep，2015，5：9211.DOI：10.1038/srep09211.
［9］BOLAND P M，YURGELUN M B，BOLAND C R.Recent progress in Lynch syndrome and other familial colorectal cancer syndromes［J］.CA Cancer J Clin，2018，68（3）：217-231.DOI：10.3322/caac.21448.
［10］YOKOTA T，URA T，SHIBATA N，et al.BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer［J］.Br J Cancer，2011，104（5）：856-862.DOI：10.1038/bjc.2011.19.
［11］HSU H C，THIAM T K，LU Y J，et al.Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients［J］.Oncotarget，2016，7（16）：22257-22270.DOI：10.18632/oncotarget.8076.
［12］VAN CUTSEM E，CUYLE P-J，HUIJBERTS S，et al.BEACON CRC study safety lead-in （SLI） in patients with BRAF V600E metastatic colorectal cancer（mCRC）：efficacy and tumor markers［J/OL］.J Clin Oncol，2018［2019-08-08］.https：//www.researchgate.net/publication/323511824_BEACON_CRC_study_safety_lead-in_SLI_in_patients_with_BRAFV600E_metastatic_colorectal_cancer_mCRC_Efficacy_and_tumor_markers.
［13］GATALICA Z，VRANIC S，XIU J，et al.High microsatellite instability （MSI-H） colorectal carcinoma：a brief review of predictive biomarkers in the era of personalized medicine［J］.Fam Cancer，2016，15（3）：405-412.DOI：10.1007/s10689-016-9884-6.
［14］VAN CUTSEM E，CUYLE P，HUIJBERTS S.O-027BEACON CRC study safety lead-in：assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer［J/OL］.Annals of Oncology，2018，29［2019-08-06］.https：//www.onacademic.com/detail/journal_1000040457836810_bd96.html.

[1]	CHEN Lulu, ZHANG Liping, LI Jingwen, DONG Wenjie, WU Xin'ai. Clinical Effect and Safety of PD-1 Inhibitors plus Fruquintinib as Later-line Treatment for Metastatic Colorectal Cancer [J]. Chinese General Practice, 2023, 26(18): 2262-2267.
[2]	China Gerontological Nursing Alliance, Xiang Ya Nursing School (Xiangya Oceanwide Health Management Research Institute of Central South University), Xiangya Hospital Central South University (National Clinical Research Center for Geriatric Disorders), Beijing Hospital (National Center for Gerontology, National Clinical Research Center for Geriatric Disorders), ZENG Xianmei, HU Mingyue, FENG Hui. Clinical Practice Guideline on Non-pharmacological Interventions for Older Adults with Cognitive Dysfunction: Physical Activity [J]. Chinese General Practice, 2023, 26(16): 1927-1937,1971.
[3]	YU Rong, DONG Weiguo, TIAN Shan, WANG Ting. Clinical Research Progress on Carcinogenesis of Different Pathological Types of Colorectal Polyps [J]. Chinese General Practice, 2023, 26(14): 1790-1794.
[4]	LIANG Puzhao, TIAN Zhentao, WU Yuyi. Interpretation of the Management of Nephrolithiasis in Pregnancy: Multi-disciplinary Guidelines from an Academic Medical Center: Improving the Diagnostic and Therapeutic Capacity, and Strengthening Multi-disciplinary Collaborative Management [J]. Chinese General Practice, 2023, 26(05): 519-524.
[5]	Fangfang ZHANG, Yajing HU, Huayong HUANG, Jinhui NI, Ze YOU, Qiaoling CHANG, Li LIAO. Association of CT-assessed Sarcopenia with Postoperative Surgical Site Infections in Patients with Colorectal Cancer [J]. Chinese General Practice, 2022, 25(29): 3658-3663.
[6]	Kaiwei DU, Xia JIANG, Yuanyuan WANG, Yanjie GENG, Tian GAO, Tianhao LAN, Guiqi WANG. Application of Two Scoring Systems in Prediction of Postoperative Complications after Radical Resection of Colorectal Cancer [J]. Chinese General Practice, 2022, 25(27): 3390-3394.
[7]	Yijia TANG, Zijing WANG, Yanrui JIANG, Fan JIANG, Guanghai WANG. Interpretation of Clinical Practice Guidelines for Sleep Disorders in Children with Autism Spectrum Disorder [J]. Chinese General Practice, 2022, 25(21): 2563-2568.
[8]	CHEN Yahong . Interpretation of Global Strategy for the Diagnosis，Treatment，Management and Prevention of Chronic Obstructive Pulmonary Disease 2022 Report [J]. Chinese General Practice, 2022, 25(11): 1294-1304.
[9]	Chinese Association of Geriatric Sleep Medicine, Chinese Geriatrics Society. Chinese Consensus on Diagnosis and Assessment of Sleep Apnea Syndrome in Older Adults [J]. Chinese General Practice, 2022, 25(11): 1283-1293.
[10]	HUANG Baotao. Prediction and Management of People at High Risk of Sudden Death after Myocardial Infarction Who are not Covered by Guidelines [J]. Chinese General Practice, 2022, 25(05): 515-521.
[11]	LI Zhenghuan, ZHANG Xiaoyun, CHEN Yang, SONG Xueli, LIU Xin. Analysis of Non-pharmacological Management Strategies for Stable Chronic Obstructive Pulmonary Disease Based on 2021 GOLD's Global Strategy for the Diagnosis，Management，and Prevention of Chronic Obstructive Pulmonary Disease [J]. Chinese General Practice, 2022, 25(02): 131-138.
[12]	ZENG Zhitong，WANG Zhaoxin，WANG Hui，YU Dehua，HUANG Jiaoling，YU Wenya，ZHOU Liang，LYU Yipeng，JIN Hua，SHI Jianwei. Individualized and Precision Health Management for Diabetes：Evidence from the Latest Guidelines and Development Prospects in China　 [J]. Chinese General Practice, 2021, 24(9): 1037-1043.
[13]	LI Zhenghuan，ZHANG Xiaoyun，CHEN Yang，SONG Xueli，QIN Zhongming，LI Hong. Interpretation of the 2020 GOLD's Global Strategy for Prevention，Diagnosis and Management of COPD（Ⅰ）：Pharmacological Treatment of Stable COPD　 [J]. Chinese General Practice, 2021, 24(8): 923-929.
[14]	HU Xiyue，LIU Zheng*，WANG Xishan. Colorectal Cancer Screening：Current Strategies and Thoughts　 [J]. Chinese General Practice, 2021, 24(33): 4165-4171.
[15]	HAN Xi，LIU Jun，MA Qi，HU Shengjuan. Colorectal Cancer Screening Program in China：Recent Advances and Screening Dilemma　 [J]. Chinese General Practice, 2021, 24(33): 4172-4176.